The 3-week NASH mouse model

Key benefits
- **Get a deep evaluation** (biochemistry, histology and NAScore) of your compounds targeting NASH within 2 months.
- 1 week diet-induction and 2 weeks treatment to evaluate the impact of your drug vs. benchmarks: Our unique nutritional model develops NASH features like high ALT/AST levels, increased liver lipids, severe inflammation, and portal fibrosis within 3 weeks.

**ANIMAL MODEL**
- **Background strain**: C57BL/6J mouse
- **Our original diet-induced NASH**: 60% high fat diet supplemented with cholesterol/choleic acid (HFCC)+cyclohextrin in drinking water (HFCC+CDX)
- **Study duration**: 3 weeks
- **Reference compounds**: Obeticholic acid, semaglutide, elafibranor, firsocostat, etc.

**EFFECTS OF POSITIVE CONTROLS**

Representative H&E (left panel) and Sirius Red (right panel) staining in HFCC+CDX fed mice treated for 2 weeks with vehicle, elafibranor, semaglutide, obeticholic acid and firsocostat. Yellow circles indicate liver microvesicular steatosis and inflammatory foci, blue arrows indicate fibrosis.

**2-WEEK TREATMENT WITH CLINICAL BENCHMARKS REDUCES STEATOSIS, INFLAMMATION AND FIBROSIS SCORES**

NAFLD activity score for steatosis (upper panel), inflammation (middle panel) and fibrosis (lower panel) in HFCC+CDX fed mice treated for 2 weeks with vehicle, semaglutide, obeticholic acid and firsocostat. **p<0.01 and ***p<0.001 vs. vehicle.**